Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

By Colin Kellaher

 

Eli Lilly has agreed to pay up to $1.5 billion to acquire Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase that is developing therapies aimed at myeloproliferative neoplasms, a group of rare blood cancers.

The purchase price includes an undisclosed upfront payment, along with clinical and regulatory milestone payments, Calytrix said Monday.

Calytrix's lead asset is an investigational biparatopic antibody targeting essential thrombocythemia, a condition in which the body makes too many platelets, which can lead to blood clots and other complications; and myelofibrosis, a blood cancer characterized by the buildup of scar tissue in the bone marrow, which interferes with the production of healthy blood cells.

Eli Lilly in April agreed to pay up to $2.3 billion for Ajax Therapeutics, which is developing next-generation Janus kinase, or JAK, inhibitors for patients with myeloproliferative neoplasms.

The Indianapolis drugmaker, which is flush with cash from its market-leading weight-loss-drug franchise, has been on a shopping spree this year, striking a range of deals each valued at less than $10 billion to buy cancer biotech Kelonia Therapeutics, immunology biotech Merida Biosciences, sleep-drug maker Centessa Pharmaceuticals, genetic-medicine biotechnology company Orna Therapeutics, mental-health-focused AtaiBeckley and biotech Ventyx Biosciences.

Calytrix, based in Wellesley Hills, Mass., was founded last year by J.P. Morgan Life Sciences Private Capital, the life-sciences venture capital arm of J.P. Morgan Asset Management. The company launched with a Series A financing co-led by J.P. Morgan and Westlake BioPartners, followed by a Series B financing led by Avoro Ventures.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 16, 2026 11:54 ET (16:54 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center